Terumo Statement Regarding Production (COVID-19)
TOKYO, JAPAN – March 12, 2020 – With responsibility as a global medical device company, Terumo Corporation (TSE: 4543) ensures to act upon the following 3 key policies to combat the outbreak of the novel coronavirus disease (COVID-19) pandemic- in line with Terumo’s Group Mission, Core Values and Business Continuity Plan Policy.
- To protect the health and safety of all Terumo Associates with utmost priority.
- To maintain a stable supply of products to continuously meet global healthcare needs.
- To actively engage and contribute to the prevention and treatment of the disease, by maximizing Terumo Group’s expertise and technologies.
Specifically, in regards to production, Terumo reports the current situation as follows.
At Terumo, there are 31 manufacturing sites across the world. To date, all sites, including the factory in China, are operating steadily and there are no reports on production disruption caused by procurement difficulties of components and raw materials.
In response to the growing global risk, each of our manufacturing sites has implemented strict countermeasures to prevent the spread of COVID-19. Some examples of these countermeasures are; restriction of movement between business locations, requesting non-production associates at some of our manufacturing sites to work from home, and staggering work shift times. Terumo will carry out various countermeasures to minimize the risk of associates contracting the disease and to maintain stable production.
Currently, there are some reports of specific products sold in Japan, such as clinical thermometers, being low on supply. This temporary shortage is due to a rapid spike in demand, and is not caused by supply chain disruption. Terumo has already taken action to increase production supply.
Based on its Group Mission of “Contributing to Society through Healthcare,” Terumo will further strive to minimize the impact of the disease on the global healthcare system.
Terumo (TSE:4543) is a global leader in medical technology and has been committed to “Contributing to Society through Healthcare” for nearly 100 years. Based in Tokyo and operating globally, Terumo employs more than 25,000 associates worldwide, to provide innovative medical solutions in more than 160 countries and regions. The company started as a Japanese excellent thermometer manufacturer, and has developed many first products in the world or in Japan to bolster medical infrastructure. Now its extensive business portfolio ranges from vascular intervention and cardio-surgical solutions, blood transfusion and cell therapy technology, to medical products essential for daily clinical practice. Terumo will further strive to be of value to patients, medical professionals, and society at large.